Sarafan ChEM-H
Showing 11-15 of 15 Results
-
Patrick David Hsu
Assistant Professor of Pathology
BioPatrick Hsu is Co-Founder of the Arc Institute and Assistant Professor of Pathology at Stanford University. The Hsu lab works at the intersection of biology and machine learning to develop technologies for biological and therapeutic design. Recent contributions include the Evo series of genome foundation models and the first universally programmable DNA recombinases. Patrick received A.M. and Ph.D. degrees from Harvard University and the Broad Institute of MIT and Harvard, where he was an early pioneer of CRISPR-Cas9 technologies for genome editing. His research has been recognized by awards from the New York Times, The Atlantic, Forbes, MIT Technology Review, Vox, Rainwater Foundation, and Amgen. He serves on the scientific advisory board of Amgen and the board of Stylus Medicine, and cofounded Fast Grants for rapid science funding.
-
KC Huang
LeRa Professor and Professor of Microbiology and Immunology
Current Research and Scholarly InterestsHow do cells determine their shape and grow?
How do molecules inside cells get to the right place at the right time?
Our group tries to answer these questions using a systems biology approach, in which we integrate interacting networks of protein and lipids with the physical forces determined by the spatial geometry of the cell. We use theoretical and computational techniques to make predictions that we can verify experimentally using synthetic, chemical, or genetic perturbations. -
Adrian Hugenmatter
Director of Protein Engineering, Sarafan ChEM-H
BioDr. Adrian Hugenmatter joined ChEM-H as Director of Protein Engineering in 2021. In his role, Dr. Hugenmatter heads the Protein Engineering Laboratory at the Nucleus and is responsible for the development of therapeutic proteins at the Innovative Medicines Accelerator (IMA). Dr. Hugenmatter obtained his PhD in the laboratory of Prof. Donald Hilvert at the Swiss Federal Institute of Technology in Zurich (ETH Zurich, Switzerland), where he gained initial experience in the fields of enzymology, antibody engineering and directed evolution. Fascinated by protein engineering, he moved to the laboratory of Prof. Dan Tawfik at the Weizmann Institute of Science (Israel), where he studied molecular evolution and its application in protein design. Dr. Hugenmatter then worked for more than a decade as a researcher and team leader at Roche. During this time, he was involved in the development and optimization of several antibody lead candidates for therapeutic applications in neuroscience and oncology.
-
Paul S Humphries
Alliance Director, Innovative Medicines Accelerator (IMA)
Current Role at StanfordAlliance Director, Stanford Innovative Medicines Accelerator (IMA)
